UBS Knock-Out ABT/ DE000UH7VXQ5 /
07/10/2024 10:05:48 | Chg.-0.020 | Bid10:05:48 | Ask10:05:48 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.480EUR | -0.57% | 3.480 Bid Size: 5,000 |
3.530 Ask Size: 5,000 |
Abbott Laboratories | 74.9616 USD | 31/12/2078 | Call |
GlobeNewswire
06/08
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
GlobeNewswire
06/06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
09/05
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
25/03
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
15/03
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
14/11/2023
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
19/10/2023
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
10/10/2023
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
02/10/2023
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors